Abbott Labs entering blood glucose monitoring market with $876 mil. MediSense buy.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT CATCHES RISING GLUCOSE MONITORING STAR MEDISENSE under an $876 mil. deal announced March 29. The definitive agreement, expected to be completed within the next five weeks, would give Abbott entry to the blood glucose monitor market with Waltham, Massachusetts-based MediSense's line of biosensor-based blood glucose systems for diabetes patient self-testing.